<DOC>
	<DOCNO>NCT00004699</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine dose recombinant human insulin-like growth factor I minimize decrease need exogenous glucose support without cause hypoglycemia .</brief_summary>
	<brief_title>Dose Ranging Study Recombinant Human Insulin-like Growth Factor I Children With Hyperinsulinism</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This dose escalation study . Patients receive escalate dose recombinant human insulin-like growth factor I ( IGF-I ) . IGF-I give subcutaneously twice day . The dose IGF-I increase day 4 day . Glucose administer intravenously , necessary , prevent hypoglycemia . Following study treatment patient resume prior medication may undergo surgery . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Complement Factor I</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis hyperinsulinism ( i.e. , evidence fast hypoglycemia inadequate suppression insulin , normal pituitary adrenal function , increased insulin action ) Intractable hypoglycemia ( i.e. , persistent IV glucose requirement maintain glucose level great 60 mg/dL ) Failed standard treatment regimen diazoxide , octreotide , frequent feeding control hypoglycemia No major medical problem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>endocrine disorder</keyword>
	<keyword>hyperinsulinism</keyword>
	<keyword>rare disease</keyword>
</DOC>